Fenofibrate differentially activates PPARα-mediated lipid metabolism in rat kidney and liver
Abstract Fenofibrate, a peroxisome proliferator-activated receptor α (PPARα) agonist, is widely prescribed to treat hyperlipidemia and has therapeutic potential in liver and kidney diseases. However, fenofibrate is also associated with adverse effects, including elevated creatinine and liver and kid...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Nature Portfolio
2025-10-01
|
| Sraith: | Scientific Reports |
| Ábhair: | |
| Rochtain ar líne: | https://doi.org/10.1038/s41598-025-20731-1 |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|